Bright Minds Biosciences (DRUG) Common Equity (2020 - 2026)
Bright Minds Biosciences' (DRUG) quarterly Common Equity came in at $225.0 million in Q1 2026, up 479.14% YoY from $38.8 million in Q1 2025, and up 251.42% on a QoQ basis from $64.0 million in Q4 2025.
Bright Minds Biosciences (DRUG) Common Equity (2020 - 2026) Analysis & Trends
Bright Minds Biosciences (DRUG) has 7 years of Common Equity data on file, last reported at $225.0 million in Q1 2026.
- Quarterly Common Equity rose 479.14% year-over-year to $225.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $225.0 million (up 479.14% YoY) and the FY2025 annual result came in at $59.6 million, up 1368.96% from the prior year.
- Common Equity climbed to $225.0 million in Q1 2026, from $64.0 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $225.0 million in Q1 2026 to a low of $4.1 million in Q3 2024.
- A 5-year average of $31.3 million and a median of $8.1 million in 2022 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity tumbled 62.86% — and 2025, when it jumped 1368.96%.
- Tracing DRUG's Common Equity over 5 years: stood at $8.1 million in 2022, then plunged by 45.15% to $4.4 million in 2023, then jumped by 834.14% to $41.4 million in 2024, then jumped by 54.66% to $64.0 million in 2025, then soared by 251.42% to $225.0 million in 2026.
- The last three Common Equity figures came in at $225.0 million (Q1 2026), $64.0 million (Q4 2025), and $59.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Bright Minds Biosciences | 733.05 Mn | 733.05 Mn | - | 224.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 224.98 Mn |
| Dec 31, 2025 | 64.02 Mn |
| Sep 30, 2025 | 59.62 Mn |
| Jun 30, 2025 | 37.41 Mn |
| Mar 31, 2025 | 38.85 Mn |
| Dec 31, 2024 | 41.40 Mn |
| Sep 30, 2024 | 4.06 Mn |
| Jun 30, 2024 | 4.46 Mn |
| Mar 31, 2024 | 4.22 Mn |
| Dec 31, 2023 | 4.43 Mn |
| Sep 30, 2023 | 4.92 Mn |
| Jun 30, 2023 | 5.75 Mn |
| Mar 31, 2023 | 6.62 Mn |
| Dec 31, 2022 | 8.08 Mn |
| Sep 30, 2022 | 8.08 Mn |
| Jun 30, 2022 | 6.62 Mn |
| Mar 31, 2022 | 8.49 Mn |
| Dec 31, 2021 | 11.84 Mn |
| Sep 30, 2021 | 15.41 Mn |
| Jun 30, 2021 | 17.81 Mn |